BMS-986278

Status
Phase 2
Condition
Idiopathic Pulmonary Fibrosis
Intervention Type
Oral Drug
Funder Type
Industry

Drug Details

BMS-986278 is a potent lysophospholipid receptor antagonist (LPA1).

Study Purpose

The purpose of this study is to provide an initial evaluation of the effectiveness of BMS-986278 in participants with lung fibrosis, to demonstrate the safety of BMS-986278, and provide information on the drug levels of BMS-986278 in these participants.

Find a Clinical Trial

 

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >